PEPperPRINT granted new US patent

On July 18, 2018, Posted by , In News, By , With Comments Off on PEPperPRINT granted new US patent

PEPperPRINT latest patent covers a novel method for producing high-density peptide microarrays PEPperPRINT is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,925,509 covering a method for the generation of high-density peptide microarrays by means of a combinatorial laser induced forward…

Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

On July 10, 2018, Posted by , In Press Releases, By ,, , With Comments Off on Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

Heidelberg 10.07.2018 BioRN as cross-cutting representative of the life science community supported Boehringer Ingelheim in the organisation, promotion and execution of this successful event. Open panel discussion during the Summer Networking Reception. Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare…

Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

On July 4, 2018, Posted by , In News, By ,, , With Comments Off on Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells…

Goethe University Frankfurt / Innovectis: new cell preparations help patients after bone marrow transplantation

On June 19, 2018, Posted by , In News, By ,, , With Comments Off on Goethe University Frankfurt / Innovectis: new cell preparations help patients after bone marrow transplantation

The Goethe University Frankfurt, the DRK Blood Transfusion Service Baden-Württemberg-Hessen and the pharmaceutical company medac have concluded a license agreement for the development of mesenchymal stromal cells for the treatment of graft-versus-host disease. The licence agreement has been signed via the university technology transfer Innovectis. This life-threatening complication often occurs…

Roche joins EMBL’s Corporate Partnership Programme

On June 12, 2018, Posted by , In News, By ,, , With Comments Off on Roche joins EMBL’s Corporate Partnership Programme

Roche and EMBL join forces to create new training opportunities for young researchers                               EMBL welcomes Roche, a frontrunner in personalised healthcare and leading provider of in vitro diagnostics, to the EMBL Advanced Training Centre Corporate Partnership Programme. The new partners will develop advanced training for young investigators and the…

BioMed X and Merck extend research collaboration in oncology

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on BioMed X and Merck extend research collaboration in oncology

BioMed X announced the start of a new research project in collaboration with Merck at its Innovation Center in Heidelberg. The new team will focus on the identification of novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.     Dr. Jan Mauer, who joined the BioMed X…

Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

On May 4, 2018, Posted by , In News, By , , With Comments Off on Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the official launch of its Redirected Optimized Cell Killing (ROCK™) platform. Based on the company’s long-standing expertise in drug development and protein engineering, the ROCK™ platform enables the generation of both NK…

Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

On March 21, 2018, Posted by , In News, By , , With Comments Off on Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met…

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

On March 20, 2018, Posted by , In News, By ,, , With Comments Off on Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and Vanderbilt University announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third…

Sciomics: Solving Alzheimers with this company’s new approach?

On March 14, 2018, Posted by , In News, By , , With Comments Off on Sciomics: Solving Alzheimers with this company’s new approach?

Labiotech.eu media recently profiled our member Sciomics, a German Cancer Research Center (DKFZ) spin-off founded in 2013 by a team of researchers led by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Sciomics has developed antibody microarrays as a tool for analyzing complex protein samples. Using their expertise, they are able to address…